OrthoPediatrics (NASDAQ:KIDS) Price Target Raised to $40.00

OrthoPediatrics (NASDAQ:KIDS – Free Report) had its target price hoisted by BTIG Research from $30.00 to $40.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other analysts also recently commented on KIDS. Lake Street Capital upped their price objective on shares of OrthoPediatrics from $34.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of OrthoPediatrics in a research note on Tuesday, November 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $35.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, October 28th. Stifel Nicolaus raised their target price on shares of OrthoPediatrics from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Finally, Truist Financial raised their target price on shares of OrthoPediatrics from $22.00 to $28.00 and gave the stock a “hold” rating in a report on Wednesday, October 28th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $33.88.

Check Out Our Latest Report on KIDS

OrthoPediatrics Trading Down 2.4%

OrthoPediatrics stock opened at $31.73 on Wednesday. The stock has a 50-day moving average price of $26.05 and a 200 day moving average price of $20.66. OrthoPediatrics has a 52 week low of $14.42 and a 52 week high of $34.53. The company has a quick ratio of 2.00, a current ratio of 4.55 and a debt-to-equity ratio of 0.29.

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last issued its quarterly earnings results on Tuesday, October 27th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02). OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 12.83%. The business had revenue of $72.66 million during the quarter, compared to analyst estimates of $68.50 million. Research analysts predict that OrthoPediatrics will post -1.09 earnings per share for the current year.

Insider Transactions at OrthoPediatrics

In related news, major shareholder Squadron Capital Llc sold 302,369 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the insider directly owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David R. Pelizzon sold 302,369 shares of OrthoPediatrics stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the transaction, the director owned 6,201,764 shares of the company’s stock, valued at approximately $130,299,061.64. This represents a 4.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 2,100,000 shares of company stock worth $46,747,931 over the last quarter. 32.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On OrthoPediatrics

Hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. grew its stake in shares of OrthoPediatrics by 3.3% during the 3rd quarter. American Century Companies Inc. now owns 41,846 shares of the company’s stock worth $932,000 after purchasing an additional 1,343 shares during the period. Advisors Asset Management Inc. purchased a new position in shares of OrthoPediatrics during the 3rd quarter valued at approximately $228,000. HighMark Wealth Management LLC purchased a new position in shares of OrthoPediatrics during the 3rd quarter valued at approximately $111,000. Aquatic Capital Management LLC acquired a new position in shares of OrthoPediatrics in the 3rd quarter valued at $25,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of OrthoPediatrics by 16.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 354,958 shares of the company’s stock valued at $7,905,000 after purchasing an additional 50,246 shares during the period. Hedge funds and other institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

(Get Free Report)

OrthoPediatrics Corp. develops and markets orthopedic implants and instruments designed specifically for children and adolescents. Its products support surgeons treating a range of pediatric conditions, including fractures, spinal deformities, limb-length differences and other orthopedic disorders. The company’s portfolio includes systems for trauma and deformity correction, scoliosis treatment, limb lengthening and external fixation, as well as specialized surgical instruments. It also provides related education and support for pediatric orthopedic surgeons and care teams.

Further Reading

Analyst Recommendations for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.